Legend Biotech (NASDAQ:LEGN) Reaches New 12-Month Low Following Analyst Downgrade

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN – Get Free Report) shares reached a new 52-week low during trading on Monday after Evercore downgraded the stock from an outperform rating to an in-line rating. The company traded as low as $16.09 and last traded at $15.9850, with a volume of 2,082,893 shares changing hands. The stock had previously closed at $17.50.

Several other research firms have also recently commented on LEGN. TD Cowen reduced their target price on Legend Biotech from $29.00 to $24.00 and set a “hold” rating for the company in a research note on Wednesday, August 12th. Oppenheimer dropped their target price on Legend Biotech from $40.00 to $25.00 and set a “market perform” rating on the stock in a research report on Wednesday, November 11th. Weiss Ratings upgraded Legend Biotech from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, November 9th. Royal Bank Of Canada reduced their price target on shares of Legend Biotech from $56.00 to $50.00 and set an “outperform” rating for the company in a report on Wednesday, November 11th. Finally, Morgan Stanley dropped their price objective on shares of Legend Biotech from $49.00 to $43.00 and set an “overweight” rating on the stock in a report on Wednesday, November 11th. Nine research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $50.85.

Read Our Latest Analysis on Legend Biotech

Insider Activity at Legend Biotech

In other Legend Biotech news, Director Corazon (Corsee) D. Sanders sold 27,370 shares of Legend Biotech stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $9.46, for a total transaction of $258,920.20. Following the sale, the director owned 52,731 shares of the company’s stock, valued at $498,835.26. The trade was a 34.17% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Carlos Santos sold 5,430 shares of the business’s stock in a transaction on Monday, September 21st. The stock was sold at an average price of $9.14, for a total value of $49,630.20. Following the transaction, the chief financial officer owned 14,246 shares of the company’s stock, valued at $130,208.44. This trade represents a 27.60% decrease in their position. The SEC filing for this sale provides additional information. 0.02% of the stock is owned by company insiders.

Institutional Trading of Legend Biotech

Several large investors have recently added to or reduced their stakes in LEGN. Assenagon Asset Management S.A. acquired a new position in shares of Legend Biotech in the 2nd quarter valued at about $55,307,000. Squarepoint Ops LLC grew its position in Legend Biotech by 60.4% during the second quarter. Squarepoint Ops LLC now owns 769,252 shares of the company’s stock valued at $22,216,000 after purchasing an additional 289,772 shares in the last quarter. Renaissance Technologies LLC lifted its position in Legend Biotech by 29.5% in the 1st quarter. Renaissance Technologies LLC now owns 521,800 shares of the company’s stock worth $9,439,000 after buying an additional 119,000 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in Legend Biotech by 343.6% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 406,901 shares of the company’s stock worth $7,361,000 after buying an additional 315,176 shares in the last quarter. Finally, Tidal Investments LLC boosted its stake in shares of Legend Biotech by 34.0% during the 2nd quarter. Tidal Investments LLC now owns 240,476 shares of the company’s stock valued at $6,945,000 after buying an additional 61,023 shares during the period. 70.89% of the stock is owned by institutional investors and hedge funds.

Legend Biotech Trading Down 8.6%

The firm has a market capitalization of $3.10 billion, a PE ratio of -1,597.40 and a beta of 0.55. The firm’s fifty day moving average price is $19.57 and its 200 day moving average price is $22.12.

Legend Biotech (NASDAQ:LEGN – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. Legend Biotech had a negative return on equity of 0.03% and a negative net margin of 0.02%. The firm had revenue of $359.50 million for the quarter, compared to the consensus estimate of $361.46 million. During the same quarter in the previous year, the company posted ($0.05) earnings per share. The business’s quarterly revenue was up 32.0% compared to the same quarter last year. As a group, research analysts expect that Legend Biotech Corporation Sponsored ADR will post -0.02 EPS for the current year.

About Legend Biotech

(Get Free Report)

Legend Biotech is a biotechnology company focused on developing cell therapies for cancer, with an emphasis on chimeric antigen receptor (CAR) T-cell treatments. Founded in 2014, the company is headquartered in Somerset, New Jersey, and conducts research and development activities in the United States and China. Its lead product is CARVYKTI (ciltacabtagene autoleucel), a BCMA-directed CAR-T therapy for certain adults with relapsed or refractory multiple myeloma. Legend developed the therapy with Janssen, now part of Johnson & Johnson’s Innovative Medicine business, which collaborates on its commercialization.

See Also

Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.